Number One on Netflix is a weekly spotlight on whatever is currently the most popular thing on the world’s most popular ...

The Tarantula Nebula, also known as 30 Doradus, is revealed in an unusual light in this exceptionally deep Chandra X-ray ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

On this day 35 years ago, NASA's Voyager 1 spacecraft took a picture that changed how we see our planet. The iconic "Pale ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

Vertex secured FDA approval for JOURNAVX, a non-opioid pain treatment, marking a significant advancement in pain management. The company reached a reimbursement agreement with NHS England for ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer yesterday. The company’s shares closed yesterday ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to $550.00. Andrew Fein has given his Buy rating due ...